Diane Simeone, MD

NIH funding disruptions threaten cancer trial pipelines, stalling early detection and new therapies—what oncologists and patients face next.

Diane Simeone, MD, director of the Pancreatic Cancer Center and associate director of Translational Research at NYU Langone’s Perlmutter Cancer Center, discusses the current state of the pancreatic cancer treatment paradigm. She says it is a very exciting time for this field as there is a large body of researchers now involved.